Case update: a 60-year-old patient received the first infusion at SIMC. The nursing and medical teams completed dedicated training on drug preparation, infusion setup, pump adjustment, and ARIA monitoring. The patient completed infusion safely and left the hospital the same evening.
Alzheimer's disease is a progressive neurodegenerative disorder. With limited historical options focused on symptom management, lecanemab represents a disease-targeted therapeutic breakthrough and advances treatment toward cause-based intervention.
SIMC Neurology is staffed by senior specialists from top tertiary hospitals and supports precise diagnosis and standardized treatment through advanced neurodiagnostic testing and imaging, covering common and complex neurological diseases.